Results 141 to 150 of about 2,198 (193)

<i>RET</i> Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update. [PDF]

Genes (Basel)
Ricciardi Tenore C, Tulli E, Perrucci A, Bertozzi R, Fortuna L, Maneri G, Santonocito C, Urbani A, De Bonis M, Minucci A.   +9 more
europepmc   +1 more source

Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study. [PDF]

Biomark Res
Lu C, Xu CR, Zhang YC, Ke EE, Sun YL, Bai XY, Chen ZH, Su J, Deng Y, Hou T, Zhao F, Li M, Wang BC, Tu HY, Wang Z, Zhang XC, Chen HJ, Yang JJ, Zhong WZ, Zhou Q, Wu YL.   +20 more
europepmc   +1 more source

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer. [PDF]

Front Oncol
Wang Y, Zhang Y, Cai C, Liu X, Ren S, Zhou S.   +5 more
europepmc   +1 more source

Acquired Intergenic ANK3-RET Fusion as a Pralsetinib-Responsive Mechanism of Resistance to Osimertinib in EGFR-Mutated NSCLC

, 2021
Edyta Maria Urbanska, Jens Benn Sørensen, Linea Cecilie Melchior, Junia C. Costa, Eric Santoni‐Rugiu   +4 more
openalex   +2 more sources

Pan-cancer clinicopathological and genomic characteristics of peritoneal metastasis. [PDF]

NPJ Precis Oncol
Chen T, Yang Y, Liu X, Dong F, Wang L, Shan Y, Wang X.   +6 more
europepmc   +1 more source

A partial response to pralsetinib in pulmonary large cell neuroendocrine carcinoma harboring KIF13A-RET fusion

Li Zhang, Zhinan Xue, Heng Xu, Yan Zhang
openalex   +1 more source

Efficacy and safety of pralsetinib in patients with RET fusion positive non–small cell lung cancer: An observational real world study

Dehua Liao, Minghui Long, Jiwen Zhang, Xingyu Wei, Fei Li, Ting Yan, De-song Yang   +6 more
openalex   +1 more source

Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy. [PDF]

Eur Thyroid J
Jager EC, Sondorp LHJ, Maturi R, Antunes IF, van Hemel BM, Brouwer U, Jansen L, Zandee WT, Brouwers AH, Links TP, Coppes RP, Kruijff S.   +11 more
europepmc   +1 more source

Using Dose-Escalation and -Expansion Cohort Study as Pivotal Trial for Targeted Anticancer Drug Approval. [PDF]

JCO Precis Oncol
Huang Y, Zhu T, Zhong J, Yuan J.
europepmc   +1 more source

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. [PDF]

Oncotarget
Wu JL, Iams WT.
europepmc   +1 more source